 | | Vol. 13.12 – 31 March, 2022 |
| |
|
|
| By tagging the ECM around the mesothelium lining in mouse peritoneum, liver, and cecum, scientists showed that pre-existing matrix was transferred across organs into wounds in various injury models.
[Nature Immunology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Through various functional analyses, researchers concluded that at least 22 genes mediated carpal tunnel syndrome (CTS) risk and highlighted the role of 19 CTS variants in the biology of the ECM.
[Nature Communications] |
|
|
|
| Investigators demonstrated that gastrointestinal tissue-derived ECM hydrogels were suitable substitutes for Matrigel in gastrointestinal organoid culture.
[Nature Communications] |
|
|
|
| A hemostatic and anti-inflammatory hydrogel patch was designed for promoting diabetic wound healing, derived from dual-cross-linked methacryloyl-substituted Bletilla striata polysaccharide and gelatin via ultraviolet light.
[Small] |
|
|
|
| A stearoyl-CoA desaturase 1 (SCD1)-dependent mechanoresponsive pathway that responded to increasing matrix stiffness in the tumor microenvironment promoted hepatocellular carcinoma (HCC) invasion and metastasis through lipid metabolic reprogramming.
[Molecular Therapy] |
|
|
|
| Scientists defined type III collagen as a suppressor of scar formation and desmoplasia through its effects, in part, on myofibroblasts.
[Matrix Biology] |
|
|
|
| The authors developed endothelial cell-laden pro- and anti-angiogenic bioinks, supplemented with bioactive matrix-derived microfibers that were created from type I collagen sponges and cartilage decellularized ECM.
[Biofabrication] |
|
|
|
| IMM-H007 attenuated isoprenaline-induced cardiac fibrosis, diastolic dysfunction, α-smooth muscle actin expression, and collagen I deposition in both wild-type and AMP-activated protein kinase α2−/− mice.
[Acta Pharmacologica Sinica] |
|
|
|
| Researchers developed a tumor-chip device engineered to mimic the pancreatic ductal adenocarcinoma tumor microenvironment by incorporating patient-derived organoids and stromal cells, specifically pancreatic stellate cells and macrophages.
[Microsystems & Nanoengineering] |
|
|
|
| The authors showed that endothelial-induced astrocytes had upregulated expression of A1 astrocytic genes and exhibited a distinctive ECM remodeling profile.
[Communications Biology] |
|
|
|
| To understand the interplay between cardiomyocyte and nonmyocyte cell types in human hypertrophic cardiomyopathy (HCM), single nuclei RNA-sequencing was performed on myectomy specimens from HCM patients with left ventricular outflow tract obstruction.
[Scientific Reports] |
|
|
|
| Scientists investigated the effect of an oxidized nanocrystalline diamond coating functionalized with bone morphogenetic protein 7 (BMP-7) on human osteoblast maturation and ECM mineralization in vitro and on new bone formation in vivo.
[Scientific Reports] |
|
|
|
|
| The authors review how single and multiple human organ chip systems have been used to model complex diseases and rare genetic disorders, study host-microbiome interactions, recapitulate whole-body inter-organ physiology, and reproduce human clinical responses to drugs.
[Nature Reviews Genetics] |
|
|
|
| Scientists summarize the current knowledge around the effects of chemotherapy on both ECM remodeling and ECM-cell signaling and discuss the implications of these alterations on distinct mechanisms of chemoresistance.
[Seminars in Cancer Biology] |
|
|
|
| Investigators summarize recent work on the regulation of ECM stiffness in cancer and the effects of ECM stiffness on tumor progression, cancer immunity, and drug resistance.
[Journal of Hematology & Oncology] |
|
|
|
|
| Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced the first patient has been dosed by GlaxoSmithKline in the Phase I study of GSK4381562 in patients with solid tumors.
[Surface Oncology] |
|
|
|
| Jeune Aesthetics, Inc. announced positive proof-of-concept efficacy data from Cohort 2 of the PEARL-1 study of KB301 for the treatment of aesthetic skin conditions. KB301 leverages Krystal’s proprietary gene delivery platform to restore protein production and rebuild the underlying ECM structure.
[Krystal Biotech, Inc.] |
|
|
|
|
| June 15 – 18, 2022
San Francisco, California, United States |
|
|
|
|
|
| | The Hospital for Sick Children – Toronto, Ontario, Canada |
|
|
|
| | Augusta University – Augusta, Georgia, United States |
|
|
|
| | Mayo Clinic – Jacksonville, Florida, United States |
|
|
|
| | University of California, San Diego – La Jolla, California, United States |
|
|
|
| | The Wellcome Trust – London, England, United Kingdom |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
